预防2型糖尿病老年人认知衰退的多领域干预试验:J-MIND-糖尿病
T Sugimoto1, A Araki, H Fujita
1Takashi Sakurai, 7-430 Morioka, Obu, Aichi 474-8511, Japan, E-mail: tsakurai@ncgg.go.jp, TEL: +81-562-46-2311.
The journal of prevention of Alzheimer's disease
|November 19, 2024
概括
多领域干预并没有防止2型糖尿病老年人的认知能力下降. 然而,它显示了潜在的认知益处,改善了饮食习惯和减肥.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 内分泌学 在内分泌学.
背景情况:
- 之前没有任何试验研究过多领域干预措施,以预防2型糖尿病老年人认知能力下降.
- 认知能力下降是老年人群,特别是2型糖尿病患者的一个重大问题.
研究的目的:
- 评估全面的多领域干预措施在停止或逆转认知衰退方面的有效性.
- 评估干预对老年患者认知功能的影响,这些患者被诊断为2型糖尿病和现有的认知障碍.
主要方法:
- 这是一项为期18个月的多中心随机对照试验,在日本12家医院进行.
- 参与者是70-85岁的门诊患者,患有2型糖尿病和认知障碍.
- 该干预包括管理代谢/血管风险因素,运动,营养指导和社会参与,而不是通常的护理.
主要成果:
- 与对照组相比,多领域干预并没有显著降低初级复合认知衰退得分 (差异=0.068).
- 二次结果分析显示了对记忆功能的积极影响.
- 干预组表现出改善的饮食习惯 (增加素和肉类摄入量),并经历了体重减轻.
结论:
- 研究的多领域干预措施在预防这一群体认知衰退方面没有证明有效.
- 该试验提供了初步证据,表明此类干预措施可能产生认知效益,并积极影响饮食和体重等生活方式因素.
- 需要进一步的研究来证实这些潜在的好处,并优化干预策略.
相关概念视频
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Cognitive Development During Adulthood
58
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
58
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448


